Cytokinetics, Incorporated
CYTK
Clasificación en acciones
#2300
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Precio por acción
$62.31
Última sincronización: 2026-10-16
Capitalización bursátil
$8.66B
Cambio (1 día)
-2.51%
Cambio (1 año)
6.63%
País
US
Comercio Cytokinetics, Incorporated (CYTK)
Categoría
Healthcare
Margen Operativo de Cytokinetics, Incorporated (CYTK)
Margen Operativo al October 2026 TTM: -992.98%
Según los informes financieros más recientes y el precio de las acciones de Cytokinetics, Incorporated, el margen operativo actual (TTM) es -992.98%. Al final de 2023, el margen operativo era -6,589.71%.
Historial de Margen Operativo de Cytokinetics, Incorporated desde 2000 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -992.98% | -65.79% |
| 2024 | -2,902.72% | -55.95% |
| 2023 | -6,589.71% | 1,822.60% |
| 2022 | -342.75% | 29.56% |
| 2021 | -264.54% | 57.21% |
| 2020 | -168.27% | -54.27% |
| 2019 | -367.97% | 30.37% |
| 2018 | -282.26% | -66.72% |
| 2017 | -848.26% | -4,930.64% |
| 2016 | 17.56% | -113.45% |
| 2015 | -130.53% | 315.30% |
| 2014 | -31.43% | -71.58% |
| 2013 | -110.59% | -78.62% |
| 2012 | -517.29% | -56.86% |
| 2011 | -1,199.10% | -37.74% |
| 2010 | -1,926.08% | -6,119.00% |
| 2009 | 32.00% | -106.73% |
| 2008 | -475.68% | 14.71% |
| 2007 | -414.67% | -78.86% |
| 2006 | -1,961.56% | 291.67% |
| 2005 | -500.82% | 75.16% |
| 2004 | -285.92% | -7.20% |
| 2003 | -308.12% | 46.42% |
| 2002 | -210.43% | -3.14% |
| 2001 | -217.25% | 0.00% |
| 2000 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.03% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.